Biotech Business - May 3, 2015
Active to Lay Off 47 Workers
A month after Swedish company Active Biotech AB reported that its Phase III trial of 10TASQ10 in castration-resistant prostate cancer reached its primary endpoint but did not increase peoples’ overall survival, the company announced plans to lay off 47 people. Active Biotech and French company Ipsen collaborated on the study of 10TASQ10 (tasquinimod). While the drug reduced the risk of radiographic cancer […]
Clinical Trials - November 5, 2014
PMDD Drug Shows Promise
A candidate drug developed by Umecrine Mood AB to treat premenstrual dysphoric disorder (PMDD) showed positive results during a randomized Phase I/II study. Those taking the drug called UC1010 showed a significant reduction in PMDD symptoms compared to those taking a placebo. “UC1010 has been developed specifically to target the atypical effects of progesterone metabolites […]
